0000950170-23-026518.txt : 20230606 0000950170-23-026518.hdr.sgml : 20230606 20230606061014 ACCESSION NUMBER: 0000950170-23-026518 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230531 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230606 DATE AS OF CHANGE: 20230606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981007018 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 23994809 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 8-K 1 alks-20230531.htm 8-K 8-K
false0001520262Alkermes plc.00015202622023-05-312023-05-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 31, 2023

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

 

Ireland

 

001-35299

 

98-1007018

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

 

 

 

 

 

Connaught House, 1 Burlington Road

Dublin 4, Ireland D04 C5Y6

(Address of principal executive offices)

 

Registrant's telephone number, including area code: + 353-1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Ordinary shares, $0.01 par value

 

ALKS

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

Item 7.01 Regulation FD Disclosure.

 

On June 6, 2023, Alkermes plc (together with its subsidiaries, the “Company”) issued a press release related to the matter described in Item 8.01 below, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This Item 7.01 and Exhibit 99.1 furnished herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and this Item 7.01 and Exhibit 99.1 shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act except as expressly set forth by specific reference in such a filing.

 

Item 8.01 Other Events.

 

On May 31, 2023, the Company received a final award (the “Final Award”) from the arbitral tribunal (the “Tribunal”) in the Company’s binding arbitration proceedings with Janssen Pharmaceutica N.V. (“Janssen”), a subsidiary of Johnson & Johnson, in respect of two license agreements. The Final Award reiterates the Tribunal’s findings from, and incorporates by reference, the First Interim Award and Second Interim Award issued by the Tribunal on December 21, 2022 and April 19, 2023, respectively. In connection with the Final Award, the Company raised its financial expectations for 2023 by approximately $425 million, which includes back royalties of approximately $194 million (inclusive of interest through March 15, 2023) related to 2022 U.S. net sales of INVEGA SUSTENNA®, INVEGA TRINZA®, INVEGA HAFYERA® and CABENUVA®, and anticipated royalty revenues related to 2023 global net sales of these products. In addition, the Company is entitled to future royalty revenues from Janssen related to net sales of these products, as outlined in the Final Award.

 

This arbitration was conducted pursuant to the Institute for Conflict Prevention and Resolution (CPR) Rules for Non-Administered Arbitration before a panel of three arbitrators.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release issued by Alkermes plc on June 6, 2023.

104

 

Cover page interactive data file (embedded within the Inline XBRL document).

 

 

2


 

 

 

Note Regarding Forward-Looking Statements

Certain statements set forth or incorporated by reference in Item 8.01 above constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including, but not limited to, statements concerning the Company’s revised financial expectations for 2023 and expectations regarding future royalty revenues related to INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA and CABENUVA. The Company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others, that the Final Award may be challenged by Janssen, and those risks and uncertainties described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and in subsequent filings made by the Company with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in Item 8.01.

 

INVEGA SUSTENNA®, INVEGA TRINZA®, and INVEGA HAFYERA® are registered trademarks of Johnson & Johnson or its affiliated companies. CABENUVA® is a registered trademark of ViiV Healthcare UK (No.3) Limited.

 

 

3


 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ALKERMES PLC

 

 

Date: June 6, 2023

By:

 

/s/ David J. Gaffin

 

 

 

David J. Gaffin

 

 

 

Secretary

 

4


EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Alkermes Contacts:

 

 

For Investors:

Sandy Coombs,

+1 781 609 6377

For Media:

Katie Joyce,

+1 781 249 8927

Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and
Provides Updated Financial Expectations

— Company Raises 2023 Revenue and GAAP Net Income Expectations by Approximately $425 Million —

— Conference Call Scheduled for Today at 8:00 a.m. ET —

 

DUBLIN, June 6, 2023 Alkermes plc (Nasdaq: ALKS) today announced that on May 31, 2023 it received a final award (the Final Award) from the arbitral tribunal (the Tribunal) in its arbitration proceedings with Janssen Pharmaceutica N.V. (Janssen), a subsidiary of Johnson & Johnson, in respect of two license agreements. In connection with the Final Award, the company raised its financial expectations for 2023 by approximately $425 million, which includes back royalties of approximately $194 million (inclusive of interest through March 15, 2023) related to 2022 U.S. net sales of the long-acting INVEGA® products and CABENUVA® that the company has now received from Janssen, and anticipated royalty revenues related to 2023 global net sales of these products. In addition, the company is entitled to future royalty revenues from Janssen related to these products in 2024 and beyond as outlined in the Final Award and as summarized below.

“We are gratified to have final resolution in this arbitration. Alkermes’ technology and know-how enabled the development of the products covered by the license agreements — medicines that have benefited millions of patients around the world. From the outset, we believed strongly that Janssen was not entitled to cease paying royalties due to Alkermes on sales of these products,” said Richard Pops, Chief Executive Officer of Alkermes. “This outcome reestablishes significant cash flows to Alkermes, provides strategic capital to our balance sheet and strengthens our longer-term financial profile by clarifying the distinct royalty term for each product covered by the license agreements.”

The Final Award reiterates the Tribunal’s findings from, and incorporates by reference, the first and second Interim Awards (issued on Dec. 21, 2022 and April 19, 2023, respectively) that:

While Janssen may terminate the license agreements, it may not continue to sell Products (as defined in the license agreements) developed during the term of the license agreements without paying royalties pursuant to the terms of the respective agreements;
Back royalties related to U.S. sales in 2022 of approximately $194 million (inclusive of interest through March 15, 2023) are due to Alkermes from Janssen under the two agreements;

A separate Know-How Royalty (as defined in the applicable license agreement) term applies for each of INVEGA SUSTENNA®, INVEGA TRINZA® and INVEGA HAFYERA®, as follows:
o
The term for INVEGA SUSTENNA ends on Aug. 20, 2024;
o
The term for INVEGA TRINZA ends in the second quarter of 2030 (but no later than May 2030 when the applicable license agreement expires); and
o
The term for INVEGA HAFYERA ends in May 2030 (when the applicable license agreement expires); and
Royalties for CABENUVA® in the U.S. are owed until Dec. 31, 2036.

“We are pleased to raise our financial expectations for 2023 based on the outcome of the arbitration proceedings with Janssen. Our revised 2023 expectations reflect the payment of back royalties and interest for 2022 and the reinstatement of royalties for 2023, which we expect will increase total revenues and GAAP net income by approximately $425 million for the year,” stated Iain Brown, Chief Financial Officer of Alkermes. “We expect these royalty revenues to be incrementally accretive to Alkermes’ bottom line in 2023 and beyond as we continue to manage our business to drive profitability for the benefit of Alkermes’ shareholders.”

In accordance with the license agreements, the arbitration was conducted pursuant to the Institute for Conflict Prevention and Resolution (CPR) Rules for Non-Administered Arbitration before a panel of three arbitrators.

Updated Financial Expectations for 2023

The following financial expectations for 2023 reflect the company’s revised assumptions, based on the Final Award, that it will receive royalty payments from Janssen related to worldwide sales of the long-acting INVEGA products (INVEGA SUSTENNA, XEPLION®, INVEGA TRINZA, TREVICTA®, INVEGA HAFYERA and BYANNLI®) and CABENUVA for the full year. In May 2023, the company received payment from Janssen for back royalties related to 2022 of approximately $194 million (inclusive of interest through March 15, 2023). This payment will be recorded in the second quarter of 2023 as “Royalty and Manufacturing Revenues” and will be excluded from the company’s non-GAAP net income measure due to the one-time and out-of-period nature of the revenue. These financial expectations continue to reflect Alkermes’ combined neuroscience and oncology business for the full year, as the company works toward the planned separation of its oncology business, which it continues to expect to complete in the second half of the year.

 

All line items set forth below are according to GAAP, except as otherwise noted.

In millions (except per share amounts)

 

Updated 2023 Expectations

(Provided June 6, 2023)

Prior 2023 Expectations

(Provided April 26, 2023)


Total Revenue

 

$1,550 – $1,680

$1,130 – $1,250

VIVITROL® Net Sales

 

$380 – $410

$380 – $410

ARISTADA® Net Sales

 

$315 – $345

$315 – $345

LYBALVI® Net Sales

$180 – $205

$180 – $205

     INVEGA Franchise Royalties related to 2023

 

$265 – $280

$40 – $45*

Royalties and interest related to 2022

~$195

-

Other Revenues

$215 – $245

$215 – $245

Cost of Goods Sold

 

$230 – $250

$230 – $250

R&D Expenses

 

$370 – $400

$370 – $400

SG&A Expenses

 

$695 – $725

$695 – $725

Amortization of Intangible Assets

 

~$35

~$35

Interest Expense, Net

$5 – $10

$5 – $10

Income Tax Benefit

 

$5 – $10

$5 – $10

GAAP Net Income (Loss)

 

$225 – $265

($160) – ($200)

GAAP Earnings (Loss) per Share (Diluted)+

 

$1.31 – $1.54

($0.96) – ($1.20)

Non-GAAP Net Income†

 

$230 – $270

$0 – $40

Non-GAAP Earnings Per Share (Diluted)+

$1.34 – $1.57

$0.00 – $0.23

Capital Expenditures

$35 – $40

$35 – $40

*Previous expectations provided on April 26, 2023 reflected royalties related to sales of XEPLION/TREVICTA/BYANNLI outside of the U.S. through the end of July 2023.

+2023 per share expectations are calculated based on a weighted average basic share count of approximately 166.5 million shares outstanding and a weighted average diluted share count of approximately 171.5 million shares outstanding. Prior 2023 expectations for GAAP loss per share, presented above, were calculated using the weighted average basic share count.

†Non-GAAP Net Income excludes royalties and interest related to 2022 of approximately $195 million due to the one-time and out-of-period nature of this revenue.

Janssen Royalties Expected to be Accretive to Profitability Targets

The company expects royalties related to the Janssen license agreements to be incrementally accretive to its profitability targets. The company today reiterated its profitability targets for FY 2024 and FY 2025, which will continue to exclude royalty revenues related to worldwide sales of products covered by the Janssen license agreements in order to highlight the strength and growth of the company’s underlying neuroscience business. The company is not providing reconciliations of, or comparable GAAP measures for, the following non-GAAP profitability targets, as they are not determinable without unreasonable efforts.*

The company today reiterated its commitment to achieving:

FY 2024 non-GAAP net income margin of 25%, and EBITDA margin of 20%, of the company’s total revenues (excluding royalty revenues from Janssen).

FY 2025 non-GAAP net income margin of 30%, and EBITDA margin of 25%, of the company’s total revenues (excluding royalty revenues from Janssen).

Conference Call

Alkermes will host a conference call and webcast presentation at 8:00 a.m. EDT (1:00 p.m. BST) today, June 6, 2023, to discuss the Final Award and provide an update on the company’s financial expectations.The webcast may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Non-GAAP Financial Measures

This press release includes information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net income and non-GAAP diluted earnings per share, non-GAAP net income margin (non-GAAP net income/total revenue) and EBITDA margin (EBITDA/total revenue). These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

Non-GAAP net income adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; change in the fair value of contingent consideration; certain other one-time or non-cash items; and the income tax effect of these reconciling items.

 

The company’s management and board of directors utilize these non-GAAP financial measures to evaluate the company’s performance. The company provides these non-GAAP financial measures of the company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying


trends in ongoing operations. However, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP net income margin (non-GAAP net income/total revenue) and EBITDA margin (EBITDA/total revenue) are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP net income margin (non-GAAP net income/total revenue) and EBITDA margin (EBITDA/total revenue) should not be considered measures of the company’s liquidity.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

 

*The company has not provided full financial expectations for time periods after the year ending Dec. 31, 2023 and therefore is not providing reconciliations of, or comparable GAAP measures for, non-GAAP net income margins or EBITDA margins, for time periods after the year ending Dec. 31, 2023. Reconciliations of such forward-looking non-GAAP profitability measures to comparable GAAP measures are not determinable without unreasonable efforts due to the inherent difficulty in forecasting and quantifying certain future financial amounts necessary for such reconciliations, which amounts could have a significant impact on the company’s future financial results, including such non-GAAP profitability measures and the comparable GAAP financial measures.

 

Important Additional Information and Where to Find It

The company has filed its definitive proxy statement, accompanying WHITE proxy card and other relevant documents with the U.S. Securities and Exchange Commission (the SEC) in connection with the solicitation of proxies for the company’s 2023 Annual General Meeting of Shareholders. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and shareholders will be able to obtain a copy of the definitive proxy statement and other documents filed by the company with the SEC free of charge from the SEC’s website at www.sec.gov. In addition, copies will be available at no charge by visiting the “Investors” section of the company’s website at www.alkermes.com, as soon as reasonably practicable after such materials are filed with, or furnished to, the SEC.

Note Regarding Forward-Looking Statements

Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company’s future financial and operating performance, business plans or prospects, including the company’s


expectations regarding the payments due to the company under the license agreements with Janssen, the respective duration of the royalty term for each product under the license agreements, the company’s profitability targets and its ability to drive profitability, and the company’s revised financial expectations for 2023; and the company’s plans to separate its neuroscience and oncology businesses, including expectations regarding the anticipated timing of the planned separation. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others, that the company may not ultimately separate its oncology business in 2023 or at all; unanticipated developments, costs or difficulties that may delay or otherwise negatively affect the planned separation; the company may not be able to achieve its profitability targets in a timely manner or at all; the terms of the Final Award may be challenged by Janssen; the unfavorable outcome of arbitration or litigation, including so-called “Paragraph IV” litigation and other patent litigation, or other disputes related to the company’s products or products using the company’s proprietary technologies; clinical development activities may not be completed on time or at all; the results of the company’s development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the U.S. Food and Drug Administration (FDA) may not agree with the company’s regulatory approval strategies or components of the company’s marketing applications; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company’s products; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company’s products or an increase in the company’s financial obligations to government payers; the company’s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2022 and in subsequent filings made by the company with the SEC, which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI®, INVEGA®, INVEGA HAFYERA®, INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies. CABENUVA® is a registered trademark of ViiV Healthcare UK (No.3) Limited.


 

 

Alkermes plc and Subsidiaries

 

2023 Guidance — GAAP to Non-GAAP Adjustments

 

 

 

 

 

 

 

 

 

 

 

An itemized reconciliation between projected diluted earnings per share on a GAAP basis and projected diluted earnings per share on a non-GAAP basis is as follows:

 

 

 

 

 

 

 

 

 

 

 

(In millions, except per share data)

 

Amount

 

Shares

 

 

Earnings Per Share

 

Projected Net Income — GAAP

 

$

245.0

 

 

 

171.5

 

 

$

1.43

 

   Adjustments:

 

 

 

 

 

 

 

 

 

Share-based compensation expense

 

 

97.5

 

 

 

 

 

 

 

Depreciation expense

 

 

42.5

 

 

 

 

 

 

 

Amortization expense

 

 

35.0

 

 

 

 

 

 

 

Separation expense

 

 

21.0

 

 

 

 

 

 

 

Income tax effect related to reconciling items

 

 

3.5

 

 

 

 

 

 

 

Non-cash net interest expense

 

 

0.5

 

 

 

 

 

 

 

Royalties and interest related to 2022*

 

 

(195.0

)

 

 

 

 

 

 

Projected Net Income — Non-GAAP

 

$

250.0

 

 

 

171.5

 

 

$

1.46

 

 

 

 

 

 

 

 

 

 

Projected GAAP and non-GAAP measures reflect mid-points within ranges of estimated guidance.

 

* Pursuant to final award related to arbitration proceedings with Janssen Pharmaceutica N.V.

 

 

 

###


EX-101.PRE 3 alks-20230531_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 alks-20230531_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity File Number Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Entity Address, Country Entity Address, Country Document Type Document Type EX-101.SCH 5 alks-20230531.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 31, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 31, 2023
Entity Registrant Name Alkermes plc.
Entity Central Index Key 0001520262
Entity Emerging Growth Company false
Entity File Number 001-35299
Entity Incorporation, State or Country Code L2
Entity Tax Identification Number 98-1007018
Entity Address, Address Line One Connaught House
Entity Address, Address Line Two 1 Burlington Road
Entity Address, City or Town Dublin 4
Entity Address, Country IE
Entity Address, Postal Zip Code D04 C5Y6
City Area Code 353
Local Phone Number 1-772-8000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary shares, $0.01 par value
Trading Symbol ALKS
Security Exchange Name NASDAQ
XML 7 alks-20230531_htm.xml IDEA: XBRL DOCUMENT 0001520262 2023-05-31 2023-05-31 false 0001520262 Alkermes plc. 8-K 2023-05-31 L2 001-35299 98-1007018 Connaught House 1 Burlington Road Dublin 4 IE D04 C5Y6 353 1-772-8000 false false false false Ordinary shares, $0.01 par value ALKS NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - alks-20230531.htm 8 alks-20230531.htm alks-20230531.xsd alks-20230531_lab.xml alks-20230531_pre.xml alks-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alks-20230531.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "alks-20230531.htm" ] }, "labelLink": { "local": [ "alks-20230531_lab.xml" ] }, "presentationLink": { "local": [ "alks-20230531_pre.xml" ] }, "schema": { "local": [ "alks-20230531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alks", "nsuri": "http://www.alkermes.com/20230531", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alks-20230531.htm", "contextRef": "C_b590430b-201f-4876-8960-4f247c855c84", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alks-20230531.htm", "contextRef": "C_b590430b-201f-4876-8960-4f247c855c84", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "verboseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "verboseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230531/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-026518-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-026518-xbrl.zip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end